Allogene upgraded to Outperform from Market Perform at Citizens JMP
Citizens JMP analyst Reni Benjamin upgraded Allogene Therapeutics (ALLO) to Outperform from Market Perform with a $5 price target The firm ...
Hosted on MSN5mon
Raymond James Analyst Turns Bullish, Says Investment Banking To Drive Revenue Growth (CORRECTED)
Editor’s note: The headline of this story has been updated to remove a misspelled reference to JMP Securities. Raymond James Financial, Inc. (NYSE:RJF) shares are trading higher Wednesday.